View Important Safety Information

  • JOIN THE MOVEMENT

    Over one million patients worldwide have turned to XEOMIN—the latest neurotoxin for treatment of movement disorders and spasticity—and that number continues to grow.1*

    Left: Jan, cervical dystonia patient
    Right: Dona, blepharospasm patient

    Center: Ruben, upper limb spasticity patient

    Read patient stories

At Merz, we understand the struggles and the unique needs of adult patients with upper limb spasticity, cervical dystonia, and blepharospasm. XEOMIN was developed to help meet these unique needs.
Read more about Merz.
Read more about XEOMIN.

Reference

  1. Data on file. Raleigh, NC: Merz North America, Inc.
Please Confirm